Stock IVVD INVIVYD, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Invivyd, Inc.

Equities

IVVD

US00534A1025

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
1.84 USD +1.66% Intraday chart for Invivyd, Inc. -4.66% -53.30%
May. 31 Invivyd in General Alignment With FDA on Emergency Use Authorization Pathway for Monoclonal Covid Antibodies MT
May. 31 Invivyd Announces General Alignment with U.S. FDA on A Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal Antibodies CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Invivyd in General Alignment With FDA on Emergency Use Authorization Pathway for Monoclonal Covid Antibodies
MT
Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal Antibodies
GL
Invivyd Announces General Alignment with U.S. FDA on A Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal Antibodies
CI
Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer
GL
Invivyd, Inc. Announces Executive Changes
CI
Invivyd, Inc. Announces Management Changes
CI
Invivyd to Present Data at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and 2024 American Transplant Congress (ATC)
GL
Invivyd Elects Two New Independent Members to its Board of Directors
GL
Invivyd, Inc. Elects Two New Independent Members to its Board of Directors
CI
Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
GL
Invivyd : Q1 2024 Invivyd Earnings Conference Call
PU
Transcript : Invivyd, Inc., Q1 2024 Earnings Call, May 09, 2024
Invivyd, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights
GL
Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback
GL
Invivyd, Inc. to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback
CI
Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights
GL
Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights
AQ
Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position
GL
Invivyd Announces CEO TransitionJeremy Gowler appointed Interim CEO
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IVVD Stock
  4. News Invivyd, Inc.